Faller Peter, Hureau Christelle
Institut de Chimie, UMR 7177, CNRS-Université de Strasbourg, Strasbourg, France.
LCC-CNRS, Université de Toulouse, CNRS, Toulouse, France.
Front Chem. 2021 Jan 14;8:611227. doi: 10.3389/fchem.2020.611227. eCollection 2020.
The self-assembly of peptides and proteins into amyloid fibrils and other aggregates are linked to several diseases. One of the most studied cases is the peptide amyloid-β (Aβ), found self-assembled in Alzheimer's disease patients' brains. In test tubes, assays with chemically synthesized or recombinant Aβ are widely investigated to understand the aggregation process and to find modulators, which could be of therapeutic interest. Experience over more than a decade in our laboratory through discussions with colleagues, expertly studying the literature, and as reviewers revealed to us the widely encountered difficulty to control the aggregation and obtain reproducible results in the test tube. However, this issue is scarcely reported and discussed in the publications, which we think hampers strongly the progress in this field and can deceive newcomers. Here, we describe the difficulty and potential reasons to obtain reproducible aggregation data and propose some guidelines for working with it.
肽和蛋白质自组装成淀粉样纤维及其他聚集体与多种疾病相关。研究最多的案例之一是肽淀粉样β蛋白(Aβ),在阿尔茨海默病患者大脑中发现其呈自组装状态。在试管中,对化学合成或重组Aβ进行的实验被广泛研究,以了解聚集过程并寻找可能具有治疗意义的调节剂。在我们实验室过去十多年的经验中,通过与同事的讨论、对文献的专业研究以及作为审稿人的经历,我们发现难以在试管中控制聚集并获得可重复的结果这一问题广泛存在。然而,该问题在出版物中鲜有报道和讨论,我们认为这严重阻碍了该领域的进展,还可能误导新手。在此,我们描述了获得可重复聚集数据的困难及潜在原因,并提出了一些相关的操作指南。